Cross-border tensions between Israel and Lebanon have led to fears of an all-out war
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance compared with chemotherapy, AstraZeneca said.
This followed similar disappointing results in key lung cancer trials released earlier this month. AstraZeneca shares had dropped following that trial setback, as investors and analysts had forecast the drug could potentially be the company's next best-selling medicine.
Dato-DXd belongs to a class of drugs known as antibody drug conjugates (ADC) consisting of tumour-seeking monoclonal antibodies that are combined with a cell-killing chemotherapy payload.
"We will continue discussions with regulatory authorities and apply insights from these results to our clinical development programme for datopotamab deruxtecan in breast cancer," said AstraZeneca's Oncology R&D executive vice-president Susan Galbraith.
The drug previously met the main goals of progression-free survival in a late-stage breast cancer study.
"We remain committed to making datopotamab deruxtecan another potential option for patients who can benefit," said Daiichi Sankyo's global head of R&D Ken Takeshita.
Cross-border tensions between Israel and Lebanon have led to fears of an all-out war
More than 600 people were killed in the weeks leading up to Hasina's ouster in early August, according to a preliminary United Nations report
They were among 13 sequences reconstructed from people whose remains were found at the Oakhurst shelter and lived 1,300-10,000 years ago
Union boss calls winter fuel payments cut 'cruel'
More than 540 millimetres of rainfall was recorded in Wajima in the 72 hours to Sunday morning — the heaviest continuous rain since comparative data became available in 1976
Heavy rains flood Gaza displacement camps
Opposition politicians from the left say they will challenge Barnier's government with a no-confidence motion, with far-right politicians also slamming its composition
Labour to make parental leave, sick pay and protection from unfair dismissal available from the first day on the job, although probation periods would remain in place